In a recent article by Suzanne Elvidge, published in BiopharmaDIVE, Metabiomics was highlighted as a clinical development leader that is exploring the links between microbiota and colon cancer. The article, titled “Hunting for the ‘good’ and the ‘bad’ Bacteria in the Microbiome” acknowledged the rapid growth in the field, highlighted several key companies and the technologies and applications being pursued.
Greg Kuehn, President and COO of Metabiomics, was interviewed for the article and provided a few insights on the challenges and opportunities of developing microbiome diagnostics for detecting colon polyps and diagnosing colon cancer as well as the diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease and Colitis.
Read the article at Biopharmadive.com.